News

Sean “Diddy” Combs would have a hard time launching a comeback despite his acquittal on the most severe charges because of ...
Merck Mercuriadis aims to buy back the music rights he sold to the private equity firm while building a new investment ...
Merck Mercuriadis, the architect behind Hipgnosis’s transformation of music rights into a mainstream asset class, is making a ...
Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...
Hipgnosis, which Mercuriadis launched in 2018 to buy song rights and was sold last year, is back with bigger ambitions.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials ...
On Thursday, RFK’s Advisory Committee on Immunization Practices (ACIP) voted to recommend clesrovimab, a new RSV antibody shot made by Merck, for infants 8 months and younger who don’t have ...
Business Wire India • Link to Live Stream of Inaugural Session of Merck Foundation First Ladies Initiative – MFFLI Summit 2025: Merck Foundation, the philanthropic arm of Merck KGaA Germany, ...
U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday for recommending use of ...
From health to hair care, the experts broke down exactly how artificial intelligence is shaping Black futures and why we can’t afford to sit this one out.
This was followed by Merck & Co’s Keytruda (pembrolizumab) and a gang of rival PD-L/PD-L1 checkpoint inhibitors, which have set new standards in cancer care in many different forms of the disease.
SCHD's quality-focused approach sets it apart from other high-yield ETFs, as it focuses on financial strength and strong ...